
This study investigated the impact of sulfatide on gene expression and proliferation of human primary fibroblasts stimulated by insulin, insulin-like growth factor-1, and human growth hormone. Human fibroblasts were treated with different concentrations of sulfatide or its precursor, galactosylceramide. The results showed that both sulfatide and GalCer reduced fibroblast growth by 32% to 82% when exposed to low insulin levels. Sulfatide also demonstrated a protective effect against membrane leakage induced by H2O2. Furthermore, sulfatide influenced gene pathways related to cell cycle/growth, transforming growth factor-β function, and intracellular signaling proteins. The study suggests that incorporating sulfatide into insulin formulations may benefit diabetic patients by suppressing adverse fibroblast growth and improving well-being.
Like
Save
Share